| N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study M Farokhnia, A Azarkolah, F Adinehfar, MR Khodaie-Ardakani, ... Clinical neuropharmacology 36 (6), 185-192, 2013 | 186 | 2013 |
| Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double‐blind randomized clinical … M Farokhnia, M Shafiee Sabet, N Iranpour, A Gougol, H Yekehtaz, ... Human Psychopharmacology: Clinical and Experimental 29 (4), 351-359, 2014 | 182 | 2014 |
| A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous … N Shahmansouri, M Farokhnia, SH Abbasi, SE Kassaian, AAN Tafti, ... Journal of Affective disorders 155, 216-222, 2014 | 176 | 2014 |
| Education attainment and alcohol binge drinking: diminished returns of Hispanics in Los Angeles S Assari, M Farokhnia, R Mistry Behavioral Sciences 9 (1), 9, 2019 | 148 | 2019 |
| Cardiovascular considerations in antidepressant therapy: an evidence-based review H Yekehtaz, M Farokhnia, S Akhondzadeh The Journal of Tehran University Heart Center 8 (4), 169, 2013 | 141 | 2013 |
| N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and … M Nikoo, H Radnia, M Farokhnia, MR Mohammadi, S Akhondzadeh Clinical neuropharmacology 38 (1), 11-17, 2015 | 126 | 2015 |
| Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double‐blind, placebo‐controlled trial A Zeinoddini, M Sorayani, E Hassanzadeh, M Arbabi, M Farokhnia, ... Depression and anxiety 32 (3), 167-173, 2015 | 123 | 2015 |
| The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study MR Lee, JD Tapocik, M Ghareeb, ML Schwandt, AA Dias, AN Le, ... Molecular psychiatry 25 (2), 461-475, 2020 | 122 | 2020 |
| Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study MR Khodaie-Ardakani, O Mirshafiee, M Farokhnia, M Tajdini, ... Psychiatry research 215 (3), 540-546, 2014 | 112 | 2014 |
| Exogenous ghrelin administration increases alcohol self-administration and modulates brain functional activity in heavy-drinking alcohol-dependent individuals M Farokhnia, EN Grodin, MR Lee, EN Oot, AN Blackburn, BL Stangl, ... Molecular psychiatry 23 (10), 2029-2038, 2018 | 109 | 2018 |
| Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study D Khajavi, M Farokhnia, A Modabbernia, M Ashrafi, SH Abbasi, M Tabrizi, ... The Journal of clinical psychiatry 73 (11), 13538, 2012 | 107 | 2012 |
| Sex differences in opioid and psychostimulant craving and relapse: a critical review C Nicolas, NE Zlebnik, M Farokhnia, L Leggio, S Ikemoto, Y Shaham, ... Pharmacological reviews 74 (1), 119-140, 2022 | 106 | 2022 |
| Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double‐blind, placebo‐controlled trial S Arabzadeh, N Ameli, A Zeinoddini, F Rezaei, M Farokhnia, ... Bipolar disorders 17 (6), 606-614, 2015 | 104 | 2015 |
| Ghrelin: From a gut hormone to a potential therapeutic target for alcohol use disorder M Farokhnia, ML Faulkner, D Piacentino, MR Lee, L Leggio Physiology & behavior 204, 49-57, 2019 | 101 | 2019 |
| The role of the ghrelin system in drug addiction LJ Zallar, M Farokhnia, BJ Tunstall, LF Vendruscolo, L Leggio International review of neurobiology 136, 89-119, 2017 | 94 | 2017 |
| Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study M Farokhnia, GR McDiarmid, MN Newmeyer, V Munjal, OA Abulseoud, ... Translational psychiatry 10 (1), 71, 2020 | 92 | 2020 |
| The microbiota, the gut and the brain in eating and alcohol use disorders: a ‘Ménage à Trois’? JE Temko, S Bouhlal, M Farokhnia, MR Lee, JF Cryan, L Leggio Alcohol and alcoholism 52 (4), 403-413, 2017 | 89 | 2017 |
| Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial A Ghaleiha, M Ghyasvand, MR Mohammadi, M Farokhnia, N Yadegari, ... Journal of Psychopharmacology 28 (7), 677-685, 2014 | 87 | 2014 |
| Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial A Gougol, N Zareh-Mohammadi, S Raheb, M Farokhnia, S Salimi, ... Journal of Psychopharmacology 29 (5), 575-581, 2015 | 78 | 2015 |
| The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission V Chuong, M Farokhnia, S Khom, CL Pince, SK Elvig, R Vlkolinsky, ... JCI insight 8 (12), 2023 | 74 | 2023 |
Lorenzo LeggioNIHVerified email at nih.gov